Product Images Doxorubicin Hydrochloride

This text seems to be a list of different clinical trials or study names. It does not offer any further details or context. Therefore, it can't provide a useful description.*

The text appears to be indicating chemical information of a substance. It provides the chemical formula C_HNO and the abbreviation for Hydrochloride (HCI), which suggests it may be a salt form. Moreover, it indicates the molecular weight (MW) of the substance as 570.00 g/mol. It is possible that this text is part of a larger chemical description, but on its own, it only provides basic information.*

Doxorubicin Hydrochloride is a cytotoxic drug available in a 10 mg dose per vial. It must be reconstituted with 5 mL 0.9% Sodium Chloride Injection and should not be prescribed without thorough knowledge of dose, indications, and toxicity. After being reconstituted, the solution is stable for 7 days at room temperature and 15 days under refrigeration. Doxorubicin Hydrochloride is used for intravenous use only and must be protected from light. The packaging insert provides complete prescribing information, including dilution recommendations before administration.*

This is a description of a medication labeled as "DOXOrubicin Hydrochloride for Injection," which is a cytotoxic agent that should not be prescribed without a thorough understanding of dose, indications, and toxicity associated with it. The medication is packaged in a vial with a sterile powder that contains doxorubicin HCI, USP 50 mg and lactose monohydrate 250 mg as an inactive ingredient. The vial should be stored at room temperature, 20° to 25°C (68° to 77°F), and should be protected from light until use. The medication is reconstituted using 25 mL 0.9% Sodium Chloride Injection, USP and is for intravenous use only. The solution is stable for 7 days at room temperature and 15 days under refrigeration after reconstitution. The packaging comes with a package insert with complete prescribing information that includes usual dosage instructions. Extravasation of the medication during administration can cause severe cellulitis, vesication, and tissue necrosis. There is additional information on the packaging about the manufacturer and manufacturing location.*